Glycomimetics Initiated At Outperform By Cowen

"We also think wholly owned GMI-1271 has generated very promising Ph1/2 data in AML showing chemo potentiation and likely improved response rates to standard of care; followup data from more patients is due 4Q16," analyst Ritu Baral wrote in a note.

Related Link: GlycoMimetics Reports Dosing Of First Patient In Phase 2 Trial Of GMI-1271 In Newly Diagnosed AML

Glycomimetics' clinical pipeline is currently focused on a class of cell-adhesion molecules called selectins that are central to bone marrow and blood cell adhesion.

Baral continued that these molecules are key to interactions between stem and blood cells and vasculature/bone marrow structural tissues. These selectin antagonists prevent interactions by competitive binding, thereby potentially preventing certain disease-related processes.

Rivipansel is currently in a late stage study in Sickle Cell Disease Vaso-Occlusive Crises (SCD VOC) with top-line data due in 2018, and the analyst believes the drug will see almost universal use in SCD crises in the United States with little to no contraindications.

"As such, we model a per treatment course of $10,000 and model relatively rapid uptake with peak sales of $1 billion in 2023 in US and EU. GLYC will receive low double digit royalties from PFE," Baral highlighted.

In addition, the analyst believes the company's other candidate GMI-1271 could become a key adjunct therapy in multiple blood cancers, representing $1.1 billion in potential peak sales in 2024 in adult acute myeloid leukemia (AML) alone.

At the time of writing, shares of GlycoMimetics were up 3.24 percent to $8.28.